Vc Thoughts, Health, Dna, Rna, Healthcare.
the additional quality assurance controls that further reduce the size of clinical batches. As the balance between the addressable market and the cost of therapy drives investor interest, biotech companies shift attention from rare diseases toward developments in non-rare indications. This brings